Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03452540 |
Recruitment Status :
Terminated
(Company Decision)
First Posted : March 2, 2018
Results First Posted : July 29, 2022
Last Update Posted : July 29, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Severe Acute Decompensated Alcoholic Hepatitis | Drug: 1000mg DS102 (BID) | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 9 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis. |
Actual Study Start Date : | November 28, 2018 |
Actual Primary Completion Date : | June 19, 2019 |
Actual Study Completion Date : | March 31, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: 1000mg DS102 (BID)
Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
|
Drug: 1000mg DS102 (BID)
Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days. |
- Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and SUSARs. [ Time Frame: Up to 28 days. ]To evaluate the safety of orally administered DS102 in the treatment of adult patients with severe acute decompensated AH.
- Descriptive Statistics for Plasma Total 15(S)-HEPE and Unesterified 15(S)-HEPE Pharmacokinetic Results for 1000 mg BD DS102 Administered Orally Twice-daily to Patients With Alcoholic Hepatitis [ Time Frame: Up to 7 days ]Descriptive Statistics for Plasma Total 15(S)-HEPE and Unesterified 15(S)-HEPE Pharmacokinetic Results for 1000 mg BD DS102 Administered Orally Twice-daily to Patients with Alcoholic Hepatitis.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female patients aged 18 years and older
- Total bilirubin of ≥ 5 mg/dl (85μmol/l)
- Patients with definite or probable AH
- MELD ≥18 at baseline visit
- MDF ≥32 at baseline visit
- AST ≥50 U/L
- AST':ALT ratio > 1.5
-
Female patients, or female partners of male patients, of child bearing potential must use highly effective birth control methods or have a sterilised partner for the duration of the study. Highly effective birth control methods are defined as methods that can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include intrauterine device or sexual abstinence.
Note: A woman is considered of child bearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy Note: Hormonal contraceptives are contraindicated in patients with severe hepatic diseases and are not acceptable as a birth control method in this study Note: Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject
- Patient and/or legally authorised representative must provide informed consent
- Able to swallow the provided study medication
- Not eligible for liver transplant during this hospitalisation
Exclusion Criteria:
- Pregnant or lactating females.
- Spontaneous liver function improvement defined by decrease of bilirubin level and MDF of >10% within 5 days of hospital admission
- Grade 4 hepatic encephalopathy (West Haven Criteria)
- Type 1 hepatorenal syndrome (HRS) or a serum creatinine >2 x ULN or the requirement for haemodialysis
- History of hypersensitivity to any substance in DS102 capsules or placebo capsules.
- Alcohol abstinence of >6 weeks prior to screening
- Duration of clinically apparent jaundice >3 months prior to baseline
-
Other causes of liver disease including:
- Evidence of chronic viral hepatitis (Hepatitis B DNA positive or HCV RNA positive)
- Biliary obstruction
- Hepatocellular carcinoma
- Wilsons disease
- Budd Chiari Syndrome
- Non-alcoholic fatty liver disease
- History of or active non-liver malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas).
- Previous entry into the study
- AST >400 U/L or ALT >270 U/L
- Treatment with any experimental drug within 30 days prior to Day 0 visit (Baseline), or 5 half-lives (whichever is longer).
- Patients who have used dietary supplements rich in omega-3 or omega-6 fatty acids in the four weeks prior to baseline.
- Patients dependent on inotropic support (adrenaline or noradrenaline), including Terlipressin
- Active variceal haemorrhage on this admission requiring more than 2 units of blood to maintain haemoglobin level within 48 hours
- Presence of refractory ascites
- Untreated or unresolved sepsis
- Patients with cerebral haemorrhage, extensive retinal haemorrhage, acute myocardial infarction (within last 6 weeks) or severe cardiac arrhythmias (not including atrial fibrillation)
- Known infection with HIV at screening.
- Significant systemic or major illnesses other than liver disease that, in the opinion of the investigator, would preclude or interfere with treatment with DS102 and/or adequate follow up.
- Previous liver transplantation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03452540
United States, Florida | |
Schiff Center for Liver Diseases (University Hospital Miami) | |
Miami, Florida, United States, 33136 | |
Cleveland Clinic Florida | |
Miami, Florida, United States, 33331 | |
United States, Kansas | |
Kansas University Medical Center | |
Kansas City, Kansas, United States, 66160 | |
United States, Massachusetts | |
Beth Israel Deaconess Medical Center | |
Boston, Massachusetts, United States, 02215 | |
United States, South Carolina | |
Medical University of South Carolina | |
Charleston, South Carolina, United States, 29425 | |
United States, Virginia | |
Bon Secours Liver Institute of Richmond and Bon Secours Liver Institute of Hampton Roads | |
Newport News, Virginia, United States, 23602 | |
Georgia | |
Batumi Referral Hospital | |
Batumi, Georgia | |
Saint Nikolozi Surgery Center | |
Kutaisi, Georgia |
Principal Investigator: | Mark Thursz | Imperial College London |
Documents provided by Afimmune:
Responsible Party: | Afimmune |
ClinicalTrials.gov Identifier: | NCT03452540 |
Other Study ID Numbers: |
DS102A-05-AH1 2018-000819-25 ( EudraCT Number ) |
First Posted: | March 2, 2018 Key Record Dates |
Results First Posted: | July 29, 2022 |
Last Update Posted: | July 29, 2022 |
Last Verified: | July 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Hepatitis A Hepatitis Hepatitis, Alcoholic Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Infections |
Enterovirus Infections Picornaviridae Infections RNA Virus Infections Liver Diseases, Alcoholic Alcohol-Induced Disorders Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders |